0%
Print report
Variant interpretation report

TP53 c.-136del, p.?

NM_000546.6:c.-136del NP_000537.3:p.? Unknown · exon 1 View identifiers
Classification
Uncertain significance

Variant description:

The TP53 NM_000546.6:c.-136del (NP_000537.3:p.?) 5' UTR variant has not previously been reported in somatic cancers (COSMIC). Based on available guidelines, this variant is considered to be a Variant of Uncertain Significance (VUS).

Five-step scale from benign to pathogenic. This variant is uncertain. Select a step to read what it means.

Uncertain.The recorded classification is uncertain significance.

In plain language

Gene-level background from the recorded interpretation.

About TP53

TP53 encodes the p53 tumor suppressor protein, a transcription factor that responds to cellular stress such as DNA damage by switching on genes that trigger cell cycle arrest, DNA repair, senescence, or programmed cell death. In healthy cells, p53 is kept at low levels by constant degradation, but stress signals stabilize and activate it to protect against damaged cells surviving and dividing. Inherited mutations in TP53 cause Li-Fraumeni syndrome, a condition marked by a high risk of developing multiple cancers at a young age. TP53 is the most commonly mutated gene across human cancers, and loss of its normal function promotes tumor growth, spread, drug resistance, and genomic instability.

LYFE Sciences is an AI system, and it can make mistakes. Criteria may be applied incorrectly, sources may be misread, and a confident-looking classification can still be wrong. Double-check every criterion and its underlying evidence before relying on any call.
01The reasoning

How it was classified

The recorded framework is ClinGen TP53 VCEP v2.4. The criteria and strengths shown below come from the saved assessment; this page does not recalculate the classification.

Recorded applied criteria

The applied criteria and their strengths are shown as assessed under the stated framework.

Pathogenic evidence criteria: 1 Benign evidence criteria: 0
Pathogenic criteria applied · 1
PM2Supporting
PM2 · supporting

Met at supporting: the variant is absent from gnomAD v2.1 and v4.1, giving observed frequency 0 below the 0.003% PM2 threshold.

Benign criteria applied · 0

No benign criterion marked as applied in the recorded assessment.

Recorded classification: Uncertain significance

VUS: PM2 (supporting) is the only applied criterion and contributes 1 point under the TP53 VCEP's point-based rule, mapping to VUS.

02The sources

Evidence at a glance

Evidence summaries and captured source records, where available. Missing entries should not be interpreted as negative findings.

SpliceAI score
0.004 maximum delta

Recorded SpliceAI maximum delta score: 0.004. Refer to the recorded PP3/BP4 rationale for interpretation.

No listed criterion applied SpliceAI ↗
No screenshot for this evidence
ClinVar submissions
Not recorded

A ClinVar laboratory submission summary was not recorded.

Context only ClinVar ↗
No screenshot for this evidence
Functional evidence
Not recorded

No standalone functional evidence summary is recorded in evidence_summary.functional.

No listed criterion applied OncoKB ↗
Somatic evidence
No matching record reported

This variant has not previously been reported in somatic cancers (COSMIC).

Context only COSMIC ↗
For specialists

Technical detail

ACMG/AMP criteria under ClinGen TP53 VCEP v2.4, with the data and sources behind each one.

28 criteria with recorded statuses: 1 met · 2 not met · 6 not assessed · 19 not applicable. Open any row for the full reasoning, the rule and the evidence behind it.

Met Not met Not assessed Not applicable

PVS1 is not applicable because c.-136del is an upstream-of-CDS exon 1 deletion outside the TP53 VCEP's named null-variant classes; PM4 and BP3 are explicitly Not Applicable in the VCEP CSPEC.

The requested VCEP PVS1 files were searched for c.-136del, p.?, and p.(=); neither file contains a matching entry.

PS4 and PP4 are not assessed because the case contains no criterion-eligible patient phenotype, VAF observations, or case-control data.

PP5, BP5, and BP6 are not applicable because the TP53 VCEP explicitly excludes these criteria.

All three computational criteria are not_applicable because NM_000546.6:c.-136del is a 5′ UTR deletion, outside the TP53 VCEP's named PP3, BP4, and BP7 variant scopes.

The VCEP reference-file searches found no matching c.-136del, p.?, g.7590805del, or g.7687483del entry; the available SpliceAI maximum delta score of 0.004 does not change scope-based non-applicability.

Met · 1

PM2 SupportingVCEPMet at supporting: the variant is absent from gnomAD v2.1 and v4.1, giving observed frequency 0 below the 0.003% PM2 threshold. Details ▾Hide ▴
Reasoning

The TP53 VCEP applies PM2 only at supporting strength when the variant allele frequency is less than 0.00003 (0.003%) in gnomAD or another large sequenced population. NM_000546.6:c.-136del is reported absent from gnomAD v2.1 and gnomAD v4.1; the observed alternate-allele frequency is therefore 0 in these queried datasets, below the VCEP threshold.

VCEP rule
This rule should be applied at supporting level. Variant should have an allele frequency of less than 0.00003 (0.003%) in gnomAD or another large sequenced population.
Evidence considered
  • gnomAD v2.1: NM_000546.6:c.-136del is absent, corresponding to no observed alternate allele and observed frequency 0.
  • gnomAD v4.1: NM_000546.6:c.-136del is absent, corresponding to no observed alternate allele and observed frequency 0.
Sources

Not met · 2 · evaluated, threshold not reached

BA1 VCEPNot met: the variant is absent from gnomAD v2.1 and v4.1, so its observed frequency is below the 0.1% BA1 threshold. Details ▾Hide ▴
Reasoning

The TP53 VCEP requires a filtering allele frequency (FAF) of at least 0.001 in a qualifying single-ancestry continental subpopulation, with at least 2,000 alleles tested and at least 2 alternate alleles present. NM_000546.6:c.-136del is reported absent from gnomAD v2.1 and gnomAD v4.1, so no qualifying population frequency or alternate-allele count reaches the BA1 threshold.

VCEP rule
Filtering allele frequency (FAF) of ≥ 0.001 or 0.1% in gnomAD continental subpopulations of a single genetic ancestry group (excluding genetic ancestry groups influenced by founder effects, such as Ashkenazi Jewish, Finnish, Amish, Middle Eastern, and “Remaining”). Genetic ancestry group must have ≥2,000 alleles tested and a minimum of 2 alleles present.
Evidence considered
  • gnomAD v2.1: NM_000546.6:c.-136del is absent; no alternate allele or population frequency is reported.
  • gnomAD v4.1: NM_000546.6:c.-136del is absent; no alternate allele or population frequency is reported.
Sources
BS1 VCEPNot met: the variant is absent from gnomAD v2.1 and v4.1, rather than having a 0.03%–less-than-0.1% qualifying population frequency. Details ▾Hide ▴
Reasoning

The TP53 VCEP requires a filtering allele frequency of at least 0.0003 but below 0.001 in a qualifying single-ancestry continental subpopulation, with at least 2,000 alleles tested and at least 2 alternate alleles present. The variant is absent from gnomAD v2.1 and gnomAD v4.1, so the available population evidence does not meet the BS1 frequency interval.

VCEP rule
Filtering allele frequency (FAF) of ≥ 0.0003 but < 0.001 in gnomAD continental subpopulations of a single genetic ancestry group (excluding genetic ancestry groups influenced by founder effects, such as Ashkenazi Jewish, Finnish, Amish, Middle Eastern, and “Remaining”). Genetic ancestry group must have ≥2,000 alleles tested and a minimum of 2 alleles present.
Evidence considered
  • gnomAD v2.1: NM_000546.6:c.-136del is absent; no alternate allele or population frequency is reported.
  • gnomAD v4.1: NM_000546.6:c.-136del is absent; no alternate allele or population frequency is reported.
Sources

Not assessed · 6 · no assessment recorded

PS2 VCEPNot assessed: no proband, parental-testing, or de novo observation is available to assign the VCEP's 1-, 2-3-, 4-7-, or ≥8-point PS2 strength. Details ▾Hide ▴
Reasoning

The TP53 VCEP evaluates PS2 by de novo evidence summarized as points, with Supporting at 1 point, Moderate at 2-3 points, Strong at 4-7 points, and Very Strong at 8 or more points. The available case evidence contains no proband cancer, confirmed or assumed maternity/paternity, parental testing, or de novo observation from which points can be assigned. The governing Table-of-LFS-Cancers-and-Points-for-PS2-and-PP1-Code-Application.pdf was searched for c.-136del, p.?, and NP_000537.3:p.?; no entry for this variant was found.

VCEP rule
≥ 8 points ... 4-7 points ... 2-3 points ... 1 point
Evidence considered
  • No proband, parental-testing, or de novo observation relevant to PS2 is present in the available case evidence.
  • Table-of-LFS-Cancers-and-Points-for-PS2-and-PP1-Code-Application.pdf: no matching row was found for c.-136del, p.?, or NP_000537.3:p.?; the table lists PS2_Supporting = 1 point, PS2_Moderate = 2-3 points, PS2 = 4-7 points, and PS2_Very Strong = ≥ 8 points.
Still missing
  • No proband cancer type or age is provided for point assignment.
  • No maternity or paternity confirmation status is provided.
  • No parental testing or confirmed de novo result is provided.
  • No entry for c.-136del, p.?, or NP_000537.3:p.? was found in Table-of-LFS-Cancers-and-Points-for-PS2-and-PP1-Code-Application.pdf.
Sources
PS4 VCEPNot assessed: no proband phenotype, LFS criteria, cancer age, or case-control counts are available to calculate the VCEP PS4 points. Details ▾Hide ▴
Reasoning

The TP53 VCEP evaluates PS4 from proband phenotype points: Revised Chompret 0.5 point, Classic LFS 1 point, and HER2-positive breast cancer before age 40 0.5 point, with total-point thresholds of Supporting 1-1.5, Moderate 2-3.5, Strong 4-7.5, and Very Strong at least 8. The case materials contain no proband phenotype, cancer diagnosis, age, Chompret/Classic LFS assessment, or case-control counts for this variant, and the literature packet contains zero PMIDs with no packet.ai_classified_papers entries to verify. The governing PS4-Points-Table.pdf was searched for c.-136del and p.?; no variant-specific entry was found. PS4 therefore cannot be assigned from the available evidence.

VCEP rule
PS4 point-based phenotype assessment
Evidence considered
  • ClinGen TP53 VCEP PS4-Points-Table.pdf: Revised Chompret = 0.5 point, Classic LFS = 1 point, HER2-positive breast cancer under 40 years = 0.5 point; PS4 thresholds are Supporting 1-1.5, Moderate 2-3.5, Strong 4-7.5, and Very Strong >=8 points.
  • Case summary: no phenotype or patient-level clinical observations are recorded; literature_packet.total_pmids = 0 and high_priority_papers and medium_priority_papers are empty.
  • Search of the governing PS4-Points-Table.pdf found no c.-136del or p.? variant-specific row.
Still missing
  • No proband-level phenotype, cancer diagnosis, age, Revised Chompret status, or Classic LFS status is available.
  • No case-control counts or matched-ancestry control frequency are available for an odds-ratio calculation.
  • No variant-specific entry was found after searching PS4-Points-Table.pdf for c.-136del and p.?.
Sources
PP1 VCEPNot assessed: no family genotypes or meioses are available to compare with the VCEP thresholds of 3-4, 5-6, or ≥7 cosegregating meioses. Details ▾Hide ▴
Reasoning

The TP53 VCEP requires cosegregation in 3-4 meioses for Supporting, 5-6 meioses for Moderate, or at least 7 meioses across more than 1 family for Strong. The available case evidence contains no affected relatives, unaffected relatives, family structure, genotype data, or meiosis count, so cosegregation cannot be assessed. The governing Table-of-LFS-Cancers-and-Points-for-PS2-and-PP1-Code-Application.pdf was searched for c.-136del, p.?, and NP_000537.3:p.?; no entry for this variant was found.

VCEP rule
Cosegregation must be observed in ≥ 7 meioses across > 1 family ... Cosegregation must be observed in 5-6 meioses in/across 1 or more families ... Cosegregation must be observed in 3-4 meioses in/across 1 or more families
Evidence considered
  • No segregation, non-segregation, family genotype, or meiosis evidence relevant to PP1 is present in the available case evidence.
  • Table-of-LFS-Cancers-and-Points-for-PS2-and-PP1-Code-Application.pdf: no matching row was found for c.-136del, p.?, or NP_000537.3:p.?; this governing file was searched as required for PP1.
Still missing
  • No family pedigree or affected-relative information is provided.
  • No genotype results for relatives are provided.
  • No meiosis count can be established.
  • No entry for c.-136del, p.?, or NP_000537.3:p.? was found in Table-of-LFS-Cancers-and-Points-for-PS2-and-PP1-Code-Application.pdf.
Sources
PP4 VCEPNot assessed: no multigene-panel blood observations or variant allele fractions are available for the VCEP PP4 thresholds. Details ▾Hide ▴
Reasoning

The TP53 VCEP PP4 rule is restricted to observations of the variant at specified low variant allele fractions in blood from multigene-panel testing: supporting requires an observation at VAF 5-35%, and moderate requires at least two independent observations at VAF 5-25%. The case contains no VAF observations, testing context, or patient phenotype data, so the rule cannot be evaluated.

VCEP rule
PP4 VAF-based phenotype rule
Evidence considered
  • TP53 VCEP PP4 rule: supporting requires observation of the variant with VAF 5-35%; moderate requires at least 2 independent observations with VAF 5-25%.
  • Case materials provide no PP4-eligible VAF observations or multigene-panel blood-testing results.
Still missing
  • No blood VAF observation or number of independent observations is available.
  • No multigene-panel testing context is available.
Sources
BS2 VCEPNot assessed: no carrier-level data identify unrelated cancer-free women aged at least 60 years from one source. Details ▾Hide ▴
Reasoning

The TP53 VCEP requires documented unrelated female carriers aged at least 60 years without cancer, all from one source, with 2–3 carriers for supporting, 4–7 for moderate, or at least 8 for strong evidence. The available evidence reports only population absence and provides no carrier-level sex, age, cancer-status, relatedness, source, or sarcoma-exclusion data, so BS2 cannot be assessed.

VCEP rule
2-3 unrelated females who have reached at least 60 years of age without cancer. These individuals all must have come from a single source (single lab, database, etc). Cases cannot be counted across sources. Individuals with a diagnosis of sarcoma ≥ 61 years of age should not be counted towards the BS2 total.
Evidence considered
  • The available gnomAD records report the variant as absent and provide no individual-level carrier information needed for BS2.
Still missing
  • Carrier-level data with sex, age, cancer status, relatedness, common source, and sarcoma history are unavailable.
Sources
BS4 VCEPNot assessed: no affected family members with genotype results are available to demonstrate the VCEP-defined lack of segregation required for BS4. Details ▾Hide ▴
Reasoning

The TP53 VCEP defines BS4 as lack of segregation in affected family members diagnosed with LFS-associated cancers described in the governing LFS cancer table. The available case evidence provides no affected family members, family genotypes, or non-segregation observations; therefore BS4 cannot be assessed.

VCEP rule
Lack of segregation in affected family members (i.e. family members diagnosed with LFS-associated cancers as described in Table of LFS Cancers and Points for PS2 and PP1 Code Application).
Evidence considered
  • No affected-family or non-segregation evidence relevant to BS4 is present in the available case evidence.
  • Table-of-LFS-Cancers-and-Points-for-PS2-and-PP1-Code-Application.pdf was consulted for the VCEP's LFS-associated cancer definitions; no matching variant row was found for c.-136del, p.?, or NP_000537.3:p.? .
Still missing
  • No affected family members with LFS-associated cancers are identified.
  • No family genotype results or non-segregation observations are provided.
  • No entry for c.-136del, p.?, or NP_000537.3:p.? was found in Table-of-LFS-Cancers-and-Points-for-PS2-and-PP1-Code-Application.pdf.
Sources
Not applicable · 19· recorded as not applicable Show reasons ▾Hide reasons ▴
PVS1 N/ANot applicable: c.-136del is a 5′-UTR exon 1 deletion, not a VCEP-listed null or canonical splice variant, with maximum SpliceAI delta 0.004. Details ▾Hide ▴
Reasoning

NM_000546.6:c.-136del is a deletion at c.-136 in exon 1, upstream of the coding sequence and outside the initiation codon, nonsense, frameshift, canonical splice-site, or exon-deletion variant classes named by the TP53 VCEP PVS1 rule. The normalized protein consequence is p.? in the case records, while the sequence validator predicts p.(=); neither establishes a protein-truncating loss-of-function consequence. SpliceAI shows a maximum delta score of 0.004, and the VCEP PVS1-Flowchart and PVS1-Splicing-Worksheet contain no entry for c.-136del, p.?, or p.(=). Therefore the VCEP-specific PVS1 criterion is not applicable.

VCEP rule
Null variant (nonsense, frameshift, canonical +/-1 or 2 splice sites, initiation codon, single or multi-exon deletion) in a gene where loss of function (LOF) is a known mechanism of disease.
Evidence considered
  • Case normalization identifies NM_000546.6:c.-136del at an upstream-of-CDS c. coordinate in exon 1; the normalized protein annotation is NP_000537.3:p.?.
  • VariantValidator places NM_000546.6:c.-136del in exon 1 and reports NP_000537.3:p.?; Mutalyzer predicts NM_000546.6(NP_000537.3):p.(=).
  • SpliceAI reports DS_AG 0.0, DS_AL 0.0, DS_DG 0.004, DS_DL 0.0, with maximum delta score 0.004.
  • Searched every notation requested—c.-136del, p.?, and p.(=)—in PVS1-Flowchart.pdf.txt and PVS1-Splicing-Worksheet.xlsx.txt; neither governing file contains a matching row.
Still missing
  • No matching c.-136del, p.?, or p.(=) entry was found in PVS1-Flowchart.pdf.txt.
  • No matching c.-136del, p.?, or p.(=) entry was found in PVS1-Splicing-Worksheet.xlsx.txt.
Sources
PS1 N/ANot applicable: c.-136del is a 5' untranslated-region deletion with no amino-acid change for comparison under the TP53 PS1 rule. Details ▾Hide ▴
Reasoning

Not applicable: the TP53 VCEP limits PS1 to comparison of variants with the same amino-acid change, but NM_000546.6:c.-136del is a 5' untranslated-region deletion with no amino-acid or residue consequence (NP_000537.3:p.(=)/p.?).

VCEP rule
Can be applied to variants asserted as Pathogenic following the _TP53_ VCEP’s specifications. ... Can be applied to variants asserted as Likely Pathogenic following the _TP53_ VCEP’s specifications.
Evidence considered
  • TP53 VCEP v2.4 PS1 rule: PS1 compares variants asserted as pathogenic or likely pathogenic following the TP53 VCEP specifications; the variant has no protein-level amino-acid consequence.
  • Variant normalization: NM_000546.6:c.-136del is upstream of the coding sequence and predicts NP_000537.3:p.(=)/p.?, not a missense residue change.
Sources
PS3 N/ANot applicable: c.-136del is an upstream 5' untranslated-region deletion with p.? rather than a missense or small in-frame deletion covered by the TP53 functional framework. Details ▾Hide ▴
Reasoning

The TP53 VCEP functional framework is restricted to protein-function assessment of missense variants and small deletions. This variant is NM_000546.6:c.-136del in the upstream 5' untranslated region, with no amino-acid change (reported as NP_000537.3:p.? and predicted as p.(=)), so it is outside the functional variant classes named by the governing flowchart and PS3 rule. The Functional-worksheet.xlsx search found no entry for c.-136del or p.?, and the flowchart search likewise found no entry for this variant. No eligible protein-functional assay can therefore be assigned to PS3 for this variant.

VCEP rule
Flowchart for application of functional codes PS3 and BS3 via protein function for missense variants (left) and small deletions (right) ... PS3_Supporting may also be applied to small deletions that demonstrate LOF on the majority of available assays
Evidence considered
  • Case normalization identifies NM_000546.6:c.-136del at an upstream, outside-CDS position and reports NP_000537.3:p.?; the predicted protein consequence is p.(=).
  • Flowchart-for-application-of-functional-rule-codes.pdf states that the functional codes are applied to missense variants and small deletions, and its small-deletion PS3 path requires loss of function by the majority of available assays.
  • Functional-worksheet.xlsx, Supplementary Table S3, was searched for c.-136del and p.?; no matching row was found, so no pre-assigned PS3 code exists for this variant.
Still missing
  • No c.-136del, p.?, or equivalent variant entry was found in Functional-worksheet.xlsx.
  • No c.-136del, p.?, or equivalent variant entry was found in Flowchart-for-application-of-functional-rule-codes.pdf.
Sources
PM1 N/ANot applicable: c.-136del is a non-missense 5' untranslated-region deletion, outside both TP53 VCEP PM1 routes requiring missense variants. Details ▾Hide ▴
Reasoning

Not applicable: the TP53 VCEP PM1 routes are restricted to missense variants in codons 175, 245, 248, 249, 273, or 282, or eligible cancerhotspots.org germline missense variants; c.-136del is a 5' untranslated-region deletion with no amino-acid residue.

VCEP rule
Missense variants within the following codons using transcript NM\_00546.4: 175, 245, 248, 249, 273, 282. This code weight can also be used for germline missense variants seen in cancerhotspots.org with ≥ 10 somatic occurrences for the same amino acid change. ... Missense variants seen in cancerhotspots.org with 2-9 somatic occurrences for the same amino acid change.
Evidence considered
  • TP53 VCEP v2.4 PM1 specifies missense variants in codons 175, 245, 248, 249, 273, or 282, with a separate cancerhotspots.org route also restricted to germline missense variants.
  • Variant normalization places NM_000546.6:c.-136del upstream of the coding sequence and assigns no amino-acid residue, so no PM1 codon or missense-hotspot route can apply.
Sources
PM3 VCEPNot applicable: the TP53 VCEP explicitly excludes PM3 for TP53/Li-Fraumeni syndrome, regardless of available phase or affected-proband observations. Details ▾Hide ▴
Reasoning

PM3 is not applicable because the ClinGen TP53 VCEP specification explicitly states that this rule does not apply to TP53/Li-Fraumeni syndrome. Therefore, phase, affected-proband observations, and trans/cis observations cannot be used to apply PM3 under this governing framework.

VCEP rule
This rule does not apply to TP53/Li-Fraumeni syndrome.
Evidence considered
  • ClinGen TP53 VCEP v2.4 criteria entry for PM3: applicability is Not applicable and the instruction states, "This rule does not apply to TP53/Li-Fraumeni syndrome."
Sources
PM4 VCEPNot applicable: the TP53 VCEP Version 2.4 CSPEC entry explicitly marks PM4 as Not Applicable. Details ▾Hide ▴
Reasoning

The TP53 VCEP Version 2.4 CSPEC criteria entry explicitly marks PM4 as Not Applicable. No PM4 evidence may therefore be assigned, regardless of the variant's upstream-of-CDS location or predicted protein annotation.

VCEP rule
Not Applicable
Evidence considered
  • The TP53 VCEP Version 2.4 CSPEC criteria entry for PM4 has applicability set to Not Applicable.
Sources
PM5 N/ANot applicable: c.-136del has no amino-acid residue, while TP53 PM5 requires a missense variant and a different classified missense variant at that residue. Details ▾Hide ▴
Reasoning

Not applicable: the TP53 VCEP PM5 rule requires a missense variant at an amino-acid residue and a different previously classified TP53 missense variant at that residue; c.-136del is a 5' untranslated-region deletion with no amino-acid residue.

VCEP rule
Missense variant at an amino acid residue where ≥2 different missense variants previously determined to be pathogenic according to the _TP53_ VCEP’s specifications have been seen before. ... Missense variant at an amino acid residue where 1 different missense variant previously determined to be pathogenic according to the _TP53_ VCEP’s specifications has been seen before. ... Missense variant at an amino acid residue where 1 different missense variant previously determined to be likely pathogenic according to the _TP53_ VCEP’s specifications has been seen before. **The previously seen likely pathogenic variant must have clinical data that demonstrates pathogenicity (i.e. PS2, PS4, PP1) in order for it to count towards PM5\_Supporting code application.**
Evidence considered
  • TP53 VCEP v2.4 PM5 requires a missense variant at an amino-acid residue where one or more different TP53 missense variants meet the VCEP pathogenicity requirements.
  • Variant normalization identifies NM_000546.6:c.-136del as an upstream noncoding deletion with NP_000537.3:p.(=)/p.? and no residue for same-residue comparison.
Sources
PM6 VCEPNot applicable: the TP53 VCEP explicitly designates PM6 as Not Applicable. Details ▾Hide ▴
Reasoning

The TP53 VCEP CSPEC entry explicitly marks PM6 as Not Applicable. No PM6 evidence is therefore evaluated under this framework.

VCEP rule
Not Applicable
Evidence considered
  • ClinGen TP53 VCEP CSPEC PM6 entry: applicability is listed as Not Applicable.
Sources
PP2 VCEPNot applicable: the TP53 VCEP explicitly designates PP2 as not applicable for this framework. Details ▾Hide ▴
Reasoning

Not applicable: the TP53 VCEP explicitly marks PP2 as not applicable, so no gene-level missense-mechanism assessment is permitted under this governing framework.

VCEP rule
Not applicable
Evidence considered
  • TP53 VCEP v2.4 PP2 entry states applicability is not applicable and gives the instruction "Not applicable."
Sources
PP3 N/ANot applicable: c.-136del is a 5′ UTR deletion, outside the VCEP PP3 scopes for missense, in-frame deletion, and splice variants. Details ▾Hide ▴
Reasoning

The variant is NM_000546.6:c.-136del, a 5′ untranslated-region deletion upstream of the coding sequence (NP_000537.3:p.?). The TP53 VCEP PP3 rule covers missense variants, single amino acid in-frame deletions, and exonic or intronic splice variants excluding ±1,2 positions; the governing flowchart/index lists missense, synonymous, and intronic variant types. A 5′ UTR deletion is outside those named PP3 scopes, so PP3 is not_applicable before considering its SpliceAI result. The required searches found no entry for this variant in Flowchart-for-application-of-PP3%2C-BP4%2C-and-BP7.pdf.txt, PP3-BP4-codes.xlsx.txt, or TP53-single-amino-acid-deletions-BayesDel-scores-(1).xlsx.txt. SpliceAI max delta score was 0.004, but that result is not used because the variant is outside PP3 scope.

VCEP rule
**Exonic (including silent variants and apparent “missense” variants or “single amino acid inframe deletions” for which there is a predicted splice effect) or Intronic Splice Variants (excluding ± 1,2 positions):** SpliceAI ≥ 0.2
Evidence considered
  • Variant normalization identifies NM_000546.6:c.-136del as outside the CDS in exon 1, with predicted protein consequence NP_000537.3:p.?.
  • ClinGen TP53 VCEP PP3 supporting rule: **Exonic (including silent variants and apparent “missense” variants or “single amino acid inframe deletions” for which there is a predicted splice effect) or Intronic Splice Variants (excluding ± 1,2 positions):** SpliceAI ≥ 0.2.
  • The governing TP53 in-silico flowchart/index names missense, synonymous, and intronic variant types for PP3/BP4/BP7; 5′ UTR deletions are not among them.
  • SpliceAI reported DS_AG 0.000, DS_AL 0.000, DS_DG 0.004, and DS_DL 0.000; maximum delta score = 0.004.
Still missing
  • No c.-136del, p.?, g.7590805del, or g.7687483del entry was found in Flowchart-for-application-of-PP3%2C-BP4%2C-and-BP7.pdf.txt.
  • No c.-136del, p.?, g.7590805del, or g.7687483del entry was found in PP3-BP4-codes.xlsx.txt.
  • No c.-136del, p.?, g.7590805del, or g.7687483del entry was found in TP53-single-amino-acid-deletions-BayesDel-scores-(1).xlsx.txt.
Sources
PP5 VCEPNot applicable: the TP53 VCEP expressly prohibits use of PP5 for this specification. Details ▾Hide ▴
Reasoning

The TP53 VCEP marks PP5 as not applicable and expressly states that the criterion is not for use. No independent reputable-source classification can override that VCEP applicability decision.

VCEP rule
This criterion is not for use as recommended by the ClinGen Sequence Variant Interpretation VCEP Review Committee.
Evidence considered
  • TP53 VCEP PP5 applicability is listed as Not Applicable for this VCEP.
Sources
BS3 N/ANot applicable: c.-136del is an upstream 5' untranslated-region deletion with p.? rather than a missense or small in-frame deletion covered by the TP53 functional framework. Details ▾Hide ▴
Reasoning

The TP53 VCEP functional framework is restricted to protein-function assessment of missense variants and small deletions. This variant is NM_000546.6:c.-136del in the upstream 5' untranslated region, with no amino-acid change (reported as NP_000537.3:p.? and predicted as p.(=)), so it is outside the functional variant classes named by the governing flowchart and BS3 rule. The Functional-worksheet.xlsx search found no entry for c.-136del or p.?, and the flowchart search likewise found no entry for this variant. No eligible protein-functional assay can therefore be assigned to BS3 for this variant.

VCEP rule
Flowchart for application of functional codes PS3 and BS3 via protein function for missense variants (left) and small deletions (right) ... BS3_Supporting may also be applied to small deletions with available Kotler et al. data that are loss of function (LOF) by the majority of available assays
Evidence considered
  • Case normalization identifies NM_000546.6:c.-136del at an upstream, outside-CDS position and reports NP_000537.3:p.?; the predicted protein consequence is p.(=).
  • Flowchart-for-application-of-functional-rule-codes.pdf states that the functional codes are applied to missense variants and small deletions, and its small-deletion BS3 path requires no loss of function by the majority of available assays.
  • Functional-worksheet.xlsx, Supplementary Table S3, was searched for c.-136del and p.?; no matching row was found, so no pre-assigned BS3 code exists for this variant.
Still missing
  • No c.-136del, p.?, or equivalent variant entry was found in Functional-worksheet.xlsx.
  • No c.-136del, p.?, or equivalent variant entry was found in Flowchart-for-application-of-functional-rule-codes.pdf.
Sources
BP1 VCEPNot applicable: the TP53 VCEP excludes BP1 because truncating variants account for only a portion of TP53 disease-causing variants. Details ▾Hide ▴
Reasoning

Not applicable: the TP53 VCEP explicitly states that BP1 does not apply to this gene because truncating variants account for only a portion of disease-causing variants.

VCEP rule
This rule code does not apply to these genes, as truncating variants account for only a portion of disease causing variants.
Evidence considered
  • TP53 VCEP v2.4 BP1 instruction: this rule code does not apply to these genes because truncating variants account for only a portion of disease-causing variants.
Sources
BP2 VCEPNot applicable: the TP53 VCEP marks BP2 Not applicable, so phase-confirmed trans observations cannot establish this criterion under version 2.4. Details ▾Hide ▴
Reasoning

BP2 is marked Not applicable in the ClinGen TP53 VCEP specification. Although the entry describes trans-phase and multiple pathogenic/likely pathogenic TP53 variant scenarios, the VCEP criterion-level applicability is Not applicable, so those observations cannot be assigned BP2 under this framework.

VCEP rule
Evidence code can be applied in either scenario: Variant is observed in trans with a pathogenic or likely pathogenic TP53 variant (phase confirmed) OR when there are 3 or more observations with a pathogenic or likely pathogenic variant when phase is unknown. In this scenario, the variant must be seen with at least two differemt pathogenic or likely pathogenic TP53 variants.
Evidence considered
  • ClinGen TP53 VCEP v2.4 criteria entry for BP2: applicability is Not applicable; its instructions describe trans-phase or three-observation scenarios but do not override the criterion-level applicability field.
Sources
BP3 VCEPNot applicable: the TP53 VCEP Version 2.4 CSPEC entry explicitly marks BP3 as Not Applicable. Details ▾Hide ▴
Reasoning

The TP53 VCEP Version 2.4 CSPEC criteria entry explicitly marks BP3 as Not Applicable. No BP3 evidence may therefore be assigned, regardless of the deletion's location or absence of a demonstrated protein effect.

VCEP rule
Not Applicable
Evidence considered
  • The TP53 VCEP Version 2.4 CSPEC criteria entry for BP3 has applicability set to Not Applicable.
Sources
BP4 N/ANot applicable: c.-136del is a 5′ UTR deletion, outside the VCEP BP4 scopes for missense, in-frame deletion, silent, and intronic variants. Details ▾Hide ▴
Reasoning

The variant is NM_000546.6:c.-136del, a 5′ untranslated-region deletion upstream of the coding sequence (NP_000537.3:p.?). The TP53 VCEP BP4 rule covers missense variants, single amino acid in-frame deletions, and silent or intronic variants outside ±1,2 positions; the governing flowchart/index lists missense, synonymous, and intronic variant types. A 5′ UTR deletion is outside those named BP4 scopes, so BP4 is not_applicable before considering its SpliceAI result. The required searches found no entry for this variant in Flowchart-for-application-of-PP3%2C-BP4%2C-and-BP7.pdf.txt, PP3-BP4-codes.xlsx.txt, or TP53-single-amino-acid-deletions-BayesDel-scores-(1).xlsx.txt. SpliceAI max delta score was 0.004, but that result is not used because the variant is outside BP4 scope.

VCEP rule
**Silent or Intronic Variants (outside ± 1,2 positions):** SpliceAI ≤ 0.1
Evidence considered
  • Variant normalization identifies NM_000546.6:c.-136del as outside the CDS in exon 1, with predicted protein consequence NP_000537.3:p.?.
  • ClinGen TP53 VCEP BP4 supporting rule: **Silent or Intronic Variants (outside ± 1,2 positions):** SpliceAI ≤ 0.1; the same rule also separately names missense and single amino acid in-frame deletion paths.
  • The governing TP53 in-silico flowchart/index names missense, synonymous, and intronic variant types for PP3/BP4/BP7; 5′ UTR deletions are not among them.
  • SpliceAI reported DS_AG 0.000, DS_AL 0.000, DS_DG 0.004, and DS_DL 0.000; maximum delta score = 0.004.
Still missing
  • No c.-136del, p.?, g.7590805del, or g.7687483del entry was found in Flowchart-for-application-of-PP3%2C-BP4%2C-and-BP7.pdf.txt.
  • No c.-136del, p.?, g.7590805del, or g.7687483del entry was found in PP3-BP4-codes.xlsx.txt.
  • No c.-136del, p.?, g.7590805del, or g.7687483del entry was found in TP53-single-amino-acid-deletions-BayesDel-scores-(1).xlsx.txt.
Sources
BP5 VCEPNot applicable: the TP53 VCEP marks BP5 as not applicable for this specification. Details ▾Hide ▴
Reasoning

The TP53 VCEP marks BP5 as not applicable, so the alternate-molecular-basis criterion cannot be applied under this governing specification regardless of whether such evidence might otherwise be available.

VCEP rule
Not applicable
Evidence considered
  • TP53 VCEP BP5 applicability is listed as Not Applicable and its instructions state Not applicable.
Sources
BP6 VCEPNot applicable: the TP53 VCEP expressly prohibits use of BP6 for this specification. Details ▾Hide ▴
Reasoning

The TP53 VCEP marks BP6 as not applicable and expressly states that the criterion is not for use. A benign report from a reputable source therefore cannot be converted into BP6 under this VCEP specification.

VCEP rule
This criterion is not for use as recommended by the ClinGen Sequence Variant Interpretation VCEP Review Committee.
Evidence considered
  • TP53 VCEP BP6 applicability is listed as Not Applicable for this VCEP.
Sources
BP7 N/ANot applicable: c.-136del is a 5′ UTR deletion, not the synonymous or intronic variant required by the VCEP BP7 rule. Details ▾Hide ▴
Reasoning

The variant is NM_000546.6:c.-136del, a 5′ untranslated-region deletion upstream of the coding sequence (NP_000537.3:p.?). The TP53 VCEP BP7 rules apply to synonymous (silent) or intronic variants, with the supporting path requiring a synonymous variant outside the core splice motif or an intronic variant at or beyond +7 to −21 positions. A 5′ UTR deletion is neither synonymous nor intronic and is outside BP7 scope, so BP7 is not_applicable before considering its SpliceAI result. The required searches found no entry for this variant in Flowchart-for-application-of-PP3%2C-BP4%2C-and-BP7.pdf.txt, PP3-BP4-codes.xlsx.txt, or TP53-single-amino-acid-deletions-BayesDel-scores-(1).xlsx.txt. SpliceAI max delta score was 0.004, but that result is not used because the variant is outside BP7 scope.

VCEP rule
A synonymous (silent) outside of the core splice motif (last three nucleotides and first nucleotide of the exon) or intronic variant at or beyond +7 to -21 positions for which SpliceAI predicts no impact to the splice consensus nor the creation of a new splice site (BP4 is met, SpliceAI ≤ 0.1). No requirement to assess for nucleotide conservation for rule application as per evidence and recommendations in Walker et al., 2023 (PMID: 37352859).
Evidence considered
  • Variant normalization identifies NM_000546.6:c.-136del as outside the CDS in exon 1, with predicted protein consequence NP_000537.3:p.?.
  • ClinGen TP53 VCEP BP7 supporting rule: A synonymous (silent) outside of the core splice motif (last three nucleotides and first nucleotide of the exon) or intronic variant at or beyond +7 to -21 positions for which SpliceAI predicts no impact to the splice consensus nor the creation of a new splice site (BP4 is met, SpliceAI ≤ 0.1). No requirement to assess for nucleotide conservation for rule application as per evidence and recommendations in Walker et al., 2023 (PMID: 37352859).
  • The governing TP53 in-silico flowchart/index names missense, synonymous, and intronic variant types for PP3/BP4/BP7; this 5′ UTR deletion is not a synonymous or intronic variant.
  • SpliceAI reported DS_AG 0.000, DS_AL 0.000, DS_DG 0.004, and DS_DL 0.000; maximum delta score = 0.004.
Still missing
  • No c.-136del, p.?, g.7590805del, or g.7687483del entry was found in Flowchart-for-application-of-PP3%2C-BP4%2C-and-BP7.pdf.txt.
  • No c.-136del, p.?, g.7590805del, or g.7687483del entry was found in PP3-BP4-codes.xlsx.txt.
  • No c.-136del, p.?, g.7590805del, or g.7687483del entry was found in TP53-single-amino-acid-deletions-BayesDel-scores-(1).xlsx.txt.
Sources

Identifiers

Gene
TP53
Transcript
NM_000546.6
Coding (HGVS c.)
NM_000546.6:c.-136del
Protein (HGVS p.)
NP_000537.3:p.?
GRCh38
chr17:7687483 CT>C
GRCh37
chr17:7590801 CT>C
Location and type
Exon 1 · unknown

Gene diagram

Every interpreted variant in TP53, mapped onto the exon structure of NM_000546.6. Select a row to find it on the plot.

TP53NM_000546.6
Fetching transcript structure from UCSC…
gnomAD v4.1 Allele count data not recorded
gnomAD v2.1 Allele count data not recorded
gnomAD-Canada v1.0 Allele count data not recorded

Statements

gnomAD v4.1

Absent from gnomAD v4.1.

gnomAD v2.1

Absent from gnomAD v2.1.

gnomAD-Canada

Absent from gnomAD-Canada v1.0.

SpliceAI and Pangolin

SpliceAI acceptor lossat -345 bp
0.000
SpliceAI acceptor gainat -424 bp
0.000
SpliceAI donor lossat +1 bp
0.000
SpliceAI donor gainat -25 bp
0.004
Pangolin splice lossmagnitude shown
-0.053
Pangolin splice gain
0.005

Other predictors

REVEL
Not available
BayesDel
Not available

How the predictions were used

PP3 N/ANot applicable: c.-136del is a 5′ UTR deletion, outside the VCEP PP3 scopes for missense, in-frame deletion, and splice variants. Details ▾Hide ▴
Reasoning

The variant is NM_000546.6:c.-136del, a 5′ untranslated-region deletion upstream of the coding sequence (NP_000537.3:p.?). The TP53 VCEP PP3 rule covers missense variants, single amino acid in-frame deletions, and exonic or intronic splice variants excluding ±1,2 positions; the governing flowchart/index lists missense, synonymous, and intronic variant types. A 5′ UTR deletion is outside those named PP3 scopes, so PP3 is not_applicable before considering its SpliceAI result. The required searches found no entry for this variant in Flowchart-for-application-of-PP3%2C-BP4%2C-and-BP7.pdf.txt, PP3-BP4-codes.xlsx.txt, or TP53-single-amino-acid-deletions-BayesDel-scores-(1).xlsx.txt. SpliceAI max delta score was 0.004, but that result is not used because the variant is outside PP3 scope.

VCEP rule
**Exonic (including silent variants and apparent “missense” variants or “single amino acid inframe deletions” for which there is a predicted splice effect) or Intronic Splice Variants (excluding ± 1,2 positions):** SpliceAI ≥ 0.2
Evidence considered
  • Variant normalization identifies NM_000546.6:c.-136del as outside the CDS in exon 1, with predicted protein consequence NP_000537.3:p.?.
  • ClinGen TP53 VCEP PP3 supporting rule: **Exonic (including silent variants and apparent “missense” variants or “single amino acid inframe deletions” for which there is a predicted splice effect) or Intronic Splice Variants (excluding ± 1,2 positions):** SpliceAI ≥ 0.2.
  • The governing TP53 in-silico flowchart/index names missense, synonymous, and intronic variant types for PP3/BP4/BP7; 5′ UTR deletions are not among them.
  • SpliceAI reported DS_AG 0.000, DS_AL 0.000, DS_DG 0.004, and DS_DL 0.000; maximum delta score = 0.004.
Still missing
  • No c.-136del, p.?, g.7590805del, or g.7687483del entry was found in Flowchart-for-application-of-PP3%2C-BP4%2C-and-BP7.pdf.txt.
  • No c.-136del, p.?, g.7590805del, or g.7687483del entry was found in PP3-BP4-codes.xlsx.txt.
  • No c.-136del, p.?, g.7590805del, or g.7687483del entry was found in TP53-single-amino-acid-deletions-BayesDel-scores-(1).xlsx.txt.
Sources
BP4 N/ANot applicable: c.-136del is a 5′ UTR deletion, outside the VCEP BP4 scopes for missense, in-frame deletion, silent, and intronic variants. Details ▾Hide ▴
Reasoning

The variant is NM_000546.6:c.-136del, a 5′ untranslated-region deletion upstream of the coding sequence (NP_000537.3:p.?). The TP53 VCEP BP4 rule covers missense variants, single amino acid in-frame deletions, and silent or intronic variants outside ±1,2 positions; the governing flowchart/index lists missense, synonymous, and intronic variant types. A 5′ UTR deletion is outside those named BP4 scopes, so BP4 is not_applicable before considering its SpliceAI result. The required searches found no entry for this variant in Flowchart-for-application-of-PP3%2C-BP4%2C-and-BP7.pdf.txt, PP3-BP4-codes.xlsx.txt, or TP53-single-amino-acid-deletions-BayesDel-scores-(1).xlsx.txt. SpliceAI max delta score was 0.004, but that result is not used because the variant is outside BP4 scope.

VCEP rule
**Silent or Intronic Variants (outside ± 1,2 positions):** SpliceAI ≤ 0.1
Evidence considered
  • Variant normalization identifies NM_000546.6:c.-136del as outside the CDS in exon 1, with predicted protein consequence NP_000537.3:p.?.
  • ClinGen TP53 VCEP BP4 supporting rule: **Silent or Intronic Variants (outside ± 1,2 positions):** SpliceAI ≤ 0.1; the same rule also separately names missense and single amino acid in-frame deletion paths.
  • The governing TP53 in-silico flowchart/index names missense, synonymous, and intronic variant types for PP3/BP4/BP7; 5′ UTR deletions are not among them.
  • SpliceAI reported DS_AG 0.000, DS_AL 0.000, DS_DG 0.004, and DS_DL 0.000; maximum delta score = 0.004.
Still missing
  • No c.-136del, p.?, g.7590805del, or g.7687483del entry was found in Flowchart-for-application-of-PP3%2C-BP4%2C-and-BP7.pdf.txt.
  • No c.-136del, p.?, g.7590805del, or g.7687483del entry was found in PP3-BP4-codes.xlsx.txt.
  • No c.-136del, p.?, g.7590805del, or g.7687483del entry was found in TP53-single-amino-acid-deletions-BayesDel-scores-(1).xlsx.txt.
Sources
BP7 N/ANot applicable: c.-136del is a 5′ UTR deletion, not the synonymous or intronic variant required by the VCEP BP7 rule. Details ▾Hide ▴
Reasoning

The variant is NM_000546.6:c.-136del, a 5′ untranslated-region deletion upstream of the coding sequence (NP_000537.3:p.?). The TP53 VCEP BP7 rules apply to synonymous (silent) or intronic variants, with the supporting path requiring a synonymous variant outside the core splice motif or an intronic variant at or beyond +7 to −21 positions. A 5′ UTR deletion is neither synonymous nor intronic and is outside BP7 scope, so BP7 is not_applicable before considering its SpliceAI result. The required searches found no entry for this variant in Flowchart-for-application-of-PP3%2C-BP4%2C-and-BP7.pdf.txt, PP3-BP4-codes.xlsx.txt, or TP53-single-amino-acid-deletions-BayesDel-scores-(1).xlsx.txt. SpliceAI max delta score was 0.004, but that result is not used because the variant is outside BP7 scope.

VCEP rule
A synonymous (silent) outside of the core splice motif (last three nucleotides and first nucleotide of the exon) or intronic variant at or beyond +7 to -21 positions for which SpliceAI predicts no impact to the splice consensus nor the creation of a new splice site (BP4 is met, SpliceAI ≤ 0.1). No requirement to assess for nucleotide conservation for rule application as per evidence and recommendations in Walker et al., 2023 (PMID: 37352859).
Evidence considered
  • Variant normalization identifies NM_000546.6:c.-136del as outside the CDS in exon 1, with predicted protein consequence NP_000537.3:p.?.
  • ClinGen TP53 VCEP BP7 supporting rule: A synonymous (silent) outside of the core splice motif (last three nucleotides and first nucleotide of the exon) or intronic variant at or beyond +7 to -21 positions for which SpliceAI predicts no impact to the splice consensus nor the creation of a new splice site (BP4 is met, SpliceAI ≤ 0.1). No requirement to assess for nucleotide conservation for rule application as per evidence and recommendations in Walker et al., 2023 (PMID: 37352859).
  • The governing TP53 in-silico flowchart/index names missense, synonymous, and intronic variant types for PP3/BP4/BP7; this 5′ UTR deletion is not a synonymous or intronic variant.
  • SpliceAI reported DS_AG 0.000, DS_AL 0.000, DS_DG 0.004, and DS_DL 0.000; maximum delta score = 0.004.
Still missing
  • No c.-136del, p.?, g.7590805del, or g.7687483del entry was found in Flowchart-for-application-of-PP3%2C-BP4%2C-and-BP7.pdf.txt.
  • No c.-136del, p.?, g.7590805del, or g.7687483del entry was found in PP3-BP4-codes.xlsx.txt.
  • No c.-136del, p.?, g.7590805del, or g.7687483del entry was found in TP53-single-amino-acid-deletions-BayesDel-scores-(1).xlsx.txt.
Sources

Statement

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.00).

0 paper records listed. No publication is explicitly linked to an applied criterion in the recorded metadata.

Screenshots represent source records captured during evidence collection. Select one to view the recorded source content.

All source links

Statements for reports

The evidence statements recorded by the interpretation pipeline. They have not been reinterpreted by the page.

gnomAD v4.1

Absent from gnomAD v4.1.

gnomAD v2.1

Absent from gnomAD v2.1.

gnomAD-Canada

Absent from gnomAD-Canada v1.0.

ClinVar

This variant is absent from ClinVar.

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.00).

Somatic

This variant has not previously been reported in somatic cancers (COSMIC).